You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Netris Pharma starts hepatocellular carcinoma study

Netris Pharma – a company developing drugs based on dependence receptor biology – has announced that the first patients have been dosed in a multicentre, single arm, proof-of-concept trial of the anti-netrin-1 antibody, NP137, in combination with atezolizumab-bevacizumab (Atezo-bev).